Molecular insights on the possible connection of SARS-CoV-2 and nicotinic acetylcholine receptors

A recent study posted to the bioRxiv* preprint server assessed the mechanism by which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and Alpha variants of concern (VOCs) inhibit the SARS-CoV-2 spike (S) protein and mitigate the risk of a multisystem inflammatory syndrome in children (MIS-C).

Study: Omicron and Alpha P680H block SARS-CoV2 spike protein from accessing cholinergic inflammatory pathway via α9-nAChR mitigating the risk of MIS-C. Image Credit: SciePro/Shutterstock
Study: Omicron and Alpha P680H block SARS-CoV2 spike protein from accessing cholinergic inflammatory pathway via α9-nAChR mitigating the risk of MIS-C. Image Credit: SciePro/Shutterstock

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Various studies have shown the different ways coronavirus disease 2019 (COVID-19) manifests in adults and children. It has also been observed that the emergence of new VOCs brings with it new symptoms and morbidities that require extensive and timely research.

About the study

The present study showed that SARS-CoV-2 Alpha and Omicron VOCs block the cholinergic inflammatory pathway responsible for MIS-C, thus reducing the risk of MIS-C complications in SARS-CoV-2-infected patients.

In the initial peptide structures obtained for the study, the C- and N- terminals were capped with NHE (simple amide) and angiotensin-converting enzyme (ACE), respectively. To determine the correlation between SARS-CoV-2 and nicotinic acetylcholine receptors (nAChRs), the researchers studied a panel of co-crystal structures along with the neurotoxin binding motif, followed by molecular dynamics (MD) simulations conducted by equilibrating the system for one nucleoside. The impact of gene mutations caused by Alpha, Omicron, and Delta VOCs was determined by performing repeated stability analysis of the SARS-CoV-2 wild-type (WT) strain. 

Results

The study results showed that neurotoxin binding motifs entailed a conserved Arginine anchor residue interacting with nAChRs. Disulfide bonds stabilized these toxins and gave rise to relatively potent and stable binding motifs. These characteristics were also found in the pre-cleavage loop in the WT S protein, wherein the spike perfectly matched the sites interacting with the DPR gene.

However, it was observed that the motif found in WT was lost post cleavage, indicating that S-nAChR interactions could occur only before cleavage, that is, in the presence of the virus in the respiratory tract, in turn, slowing down viral entry in the host.

Post MD analysis, it was observed that the SARS-CoV-2 Alpha VOC reduced the stability of the structure of the α-conotoxin binding motif. At the same time, the Delta VOC revived the motif, and the Omicron VOC prevented the interaction of the S protein with nAChR. Altogether, α9-nAChR antagonists like α-conotoxin and, to a lower degree, Delta VOC could promote the release of pro-inflammatory cytokines while Alpha and Omicron VOCs blocked this cholinergic inflammatory pathway that is responsible for MIS-C.     

Conclusion

The study findings showed that the SARS-CoV-2 Omicron VOC showed the least risk of manifesting MIS-C. Also, MD simulations presented significant structural similarities between WT SARS-CoV-2 and the motif that binds α-conotoxin and α9-nAChR. The study also indicated that viral impact on triggered inflammatory pathways occurs only if the cholinergic pathway is activated when the virus is present in the nasal mucosa or the respiratory tract.    

The researchers believed that the present study could guide further studies investigating interactions between host and pathogen and the analysis of the cholinergic pathway as a source of cytokine increase during SARS-CoV-2 infection.

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Bhavana Kunkalikar

Written by

Bhavana Kunkalikar

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kunkalikar, Bhavana. (2022, February 28). Molecular insights on the possible connection of SARS-CoV-2 and nicotinic acetylcholine receptors. News-Medical. Retrieved on November 14, 2024 from https://www.news-medical.net/news/20220228/Molecular-insights-on-the-possible-connection-of-SARS-CoV-2-and-nicotinic-acetylcholine-receptors.aspx.

  • MLA

    Kunkalikar, Bhavana. "Molecular insights on the possible connection of SARS-CoV-2 and nicotinic acetylcholine receptors". News-Medical. 14 November 2024. <https://www.news-medical.net/news/20220228/Molecular-insights-on-the-possible-connection-of-SARS-CoV-2-and-nicotinic-acetylcholine-receptors.aspx>.

  • Chicago

    Kunkalikar, Bhavana. "Molecular insights on the possible connection of SARS-CoV-2 and nicotinic acetylcholine receptors". News-Medical. https://www.news-medical.net/news/20220228/Molecular-insights-on-the-possible-connection-of-SARS-CoV-2-and-nicotinic-acetylcholine-receptors.aspx. (accessed November 14, 2024).

  • Harvard

    Kunkalikar, Bhavana. 2022. Molecular insights on the possible connection of SARS-CoV-2 and nicotinic acetylcholine receptors. News-Medical, viewed 14 November 2024, https://www.news-medical.net/news/20220228/Molecular-insights-on-the-possible-connection-of-SARS-CoV-2-and-nicotinic-acetylcholine-receptors.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Could vitamin D help COVID-19 patients? Meta-analysis highlights potential ICU reduction